Sumitomo Mitsui DS Asset Management Company Ltd Grows Position in Insulet Co. (NASDAQ:PODD)

Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 30.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,395 shares of the medical instruments supplier's stock after purchasing an additional 1,942 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Insulet were worth $2,192,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Baillie Gifford & Co. lifted its stake in shares of Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock valued at $529,669,000 after buying an additional 389,639 shares in the last quarter. Mizuho Securities USA LLC lifted its position in shares of Insulet by 5,928.1% during the third quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier's stock valued at $75,835,000 after purchasing an additional 320,416 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Insulet by 43.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock valued at $148,091,000 after purchasing an additional 193,839 shares in the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock valued at $175,697,000 after purchasing an additional 163,388 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Insulet during the third quarter valued at about $16,342,000.

Insider Activity at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Lauren Budden sold 915 shares of the company's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Insulet Stock Performance

Shares of PODD traded down $1.56 during trading hours on Friday, hitting $280.56. The company's stock had a trading volume of 474,733 shares, compared to its average volume of 528,501. The company has a market cap of $19.68 billion, a price-to-earnings ratio of 48.04, a PEG ratio of 3.61 and a beta of 1.23. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The business has a 50 day simple moving average of $271.74 and a two-hundred day simple moving average of $244.03. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46.

Analyst Ratings Changes

A number of research analysts recently weighed in on PODD shares. Wells Fargo & Company raised their price target on shares of Insulet from $290.00 to $305.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Morgan Stanley raised their price target on shares of Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, November 11th. Citigroup raised their price target on shares of Insulet from $283.00 to $310.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Barclays raised their price target on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research report on Monday, November 11th. Finally, BTIG Research lifted their price objective on shares of Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a research report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Insulet has an average rating of "Moderate Buy" and a consensus price target of $277.13.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.